Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice
Diabetic cardiomyopathy is characterized by abnormal myocardial structure or performance in the absence of coronary artery disease or significant valvular heart disease in patients with diabetes mellitus. The spectrum of diabetic cardiomyopathy ranges from subtle myocardial changes to myocardial fib...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/3/662 |
| _version_ | 1797613350765461504 |
|---|---|
| author | Chin-Feng Hsuan Sean I. F. Teng Chih-Neng Hsu Daniel Liao Allen Jiun-Wei Chang Hsiao-Lin Lee Siow-Wey Hee Yi-Cheng Chang Lee-Ming Chuang |
| author_facet | Chin-Feng Hsuan Sean I. F. Teng Chih-Neng Hsu Daniel Liao Allen Jiun-Wei Chang Hsiao-Lin Lee Siow-Wey Hee Yi-Cheng Chang Lee-Ming Chuang |
| author_sort | Chin-Feng Hsuan |
| collection | DOAJ |
| description | Diabetic cardiomyopathy is characterized by abnormal myocardial structure or performance in the absence of coronary artery disease or significant valvular heart disease in patients with diabetes mellitus. The spectrum of diabetic cardiomyopathy ranges from subtle myocardial changes to myocardial fibrosis and diastolic function and finally to symptomatic heart failure. Except for sodium–glucose transport protein 2 inhibitors and possibly bariatric and metabolic surgery, there is currently no specific treatment for this distinct disease entity in patients with diabetes. The molecular mechanism of diabetic cardiomyopathy includes impaired nutrient-sensing signaling, dysregulated autophagy, impaired mitochondrial energetics, altered fuel utilization, oxidative stress and lipid peroxidation, advanced glycation end-products, inflammation, impaired calcium homeostasis, abnormal endothelial function and nitric oxide production, aberrant epidermal growth factor receptor signaling, the activation of the renin–angiotensin–aldosterone system and sympathetic hyperactivity, and extracellular matrix accumulation and fibrosis. Here, we summarize several important emerging treatments for diabetic cardiomyopathy targeting specific molecular mechanisms, with evidence from preclinical studies and clinical trials. |
| first_indexed | 2024-03-11T06:54:35Z |
| format | Article |
| id | doaj.art-7b7f1d4d17d547edb38ba35c6a23926a |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T06:54:35Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-7b7f1d4d17d547edb38ba35c6a23926a2023-11-17T09:43:46ZengMDPI AGBiomedicines2227-90592023-02-0111366210.3390/biomedicines11030662Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical PracticeChin-Feng Hsuan0Sean I. F. Teng1Chih-Neng Hsu2Daniel Liao3Allen Jiun-Wei Chang4Hsiao-Lin Lee5Siow-Wey Hee6Yi-Cheng Chang7Lee-Ming Chuang8Division of Cardiology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 824, TaiwanDepartment of Cardiology, Ming-Sheng General Hospital, Taoyuan 330, TaiwanDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin 640, TaiwanGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei 100, TaiwanGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei 100, TaiwanGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei 100, TaiwanDepartment of Internal Medicine, Division of Endocrinology and Metabolism, National Taiwan University Hospital, Taipei 100, TaiwanGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei 100, TaiwanDepartment of Internal Medicine, Division of Endocrinology and Metabolism, National Taiwan University Hospital, Taipei 100, TaiwanDiabetic cardiomyopathy is characterized by abnormal myocardial structure or performance in the absence of coronary artery disease or significant valvular heart disease in patients with diabetes mellitus. The spectrum of diabetic cardiomyopathy ranges from subtle myocardial changes to myocardial fibrosis and diastolic function and finally to symptomatic heart failure. Except for sodium–glucose transport protein 2 inhibitors and possibly bariatric and metabolic surgery, there is currently no specific treatment for this distinct disease entity in patients with diabetes. The molecular mechanism of diabetic cardiomyopathy includes impaired nutrient-sensing signaling, dysregulated autophagy, impaired mitochondrial energetics, altered fuel utilization, oxidative stress and lipid peroxidation, advanced glycation end-products, inflammation, impaired calcium homeostasis, abnormal endothelial function and nitric oxide production, aberrant epidermal growth factor receptor signaling, the activation of the renin–angiotensin–aldosterone system and sympathetic hyperactivity, and extracellular matrix accumulation and fibrosis. Here, we summarize several important emerging treatments for diabetic cardiomyopathy targeting specific molecular mechanisms, with evidence from preclinical studies and clinical trials.https://www.mdpi.com/2227-9059/11/3/662diabetic cardiomyopathyemerging therapymechanism |
| spellingShingle | Chin-Feng Hsuan Sean I. F. Teng Chih-Neng Hsu Daniel Liao Allen Jiun-Wei Chang Hsiao-Lin Lee Siow-Wey Hee Yi-Cheng Chang Lee-Ming Chuang Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice Biomedicines diabetic cardiomyopathy emerging therapy mechanism |
| title | Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice |
| title_full | Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice |
| title_fullStr | Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice |
| title_full_unstemmed | Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice |
| title_short | Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice |
| title_sort | emerging therapy for diabetic cardiomyopathy from molecular mechanism to clinical practice |
| topic | diabetic cardiomyopathy emerging therapy mechanism |
| url | https://www.mdpi.com/2227-9059/11/3/662 |
| work_keys_str_mv | AT chinfenghsuan emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT seanifteng emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT chihnenghsu emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT danielliao emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT allenjiunweichang emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT hsiaolinlee emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT siowweyhee emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT yichengchang emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice AT leemingchuang emergingtherapyfordiabeticcardiomyopathyfrommolecularmechanismtoclinicalpractice |